Lexeo to Webcast Interim Phase 1/2 Data on LX2006 for Friedreich Ataxia on July 15, 2024

NEW YORK, July 11, 2024 — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company focusing on innovative treatments for genetically-defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, has announced an upcoming investor webcast. Scheduled for Monday, July 15, 2024, at 8:00 AM ET, the webcast will present interim clinical data on LX2006, an AAVrh10.hFXN gene therapy targeting Friedreich ataxia (FA) cardiomyopathy.

The presentation will start with an overview of the natural progression of FA cardiomyopathy and summarize the key clinical endpoints. It will then cover interim data from the ongoing SUNRISE-FA Phase 1/2 clinical trial (NCT05445323) and the current Weill Cornell Medicine investigator-initiated trial (NCT05302271). Future steps for the program will also be discussed. Interested parties can register for the webcast on Lexeo's website under the News & Events section, where the presentation will also be available on-demand post-event.

The SUNRISE-FA trial is a multicenter, 52-week, dose-ascending, open-label study assessing the safety and initial efficacy of LX2006 in patients with FA cardiomyopathy. LX2006 is administered intravenously in a one-time infusion to patients in at least two dosage cohorts, with a potential third cohort receiving a dose of 1.2x10^12 vg/kg. Moreover, the investigators at Weill Cornell Medicine are conducting a Phase 1A study of AAVrh.10hFXN, referred to as LX2006 by Lexeo, in a single-site, 52-week, dose-ascending, open-label trial. This trial also assesses the safety and preliminary efficacy of AAVrh.10hFXN in FA cardiomyopathy patients, administering the therapy intravenously to two ascending-dose cohorts consisting of five participants each.

In April 2024, Lexeo acquired certain intellectual property rights from Weill Cornell Medicine, including rights to current and future data from the ongoing Phase 1A trial of AAVrh.10hFXN.

Lexeo Therapeutics, based in New York City, is dedicated to transforming healthcare by leveraging pioneering science to fundamentally change the treatment of genetically-defined cardiovascular diseases and APOE4-associated Alzheimer’s disease. The company employs a step-by-step development approach, utilizing early proof-of-concept functional and biomarker data to advance its pipeline focused on cardiovascular and APOE4-associated Alzheimer's disease programs.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!